ATE469921T1 - Lpa-haltige verbindungen - Google Patents

Lpa-haltige verbindungen

Info

Publication number
ATE469921T1
ATE469921T1 AT04739024T AT04739024T ATE469921T1 AT E469921 T1 ATE469921 T1 AT E469921T1 AT 04739024 T AT04739024 T AT 04739024T AT 04739024 T AT04739024 T AT 04739024T AT E469921 T1 ATE469921 T1 AT E469921T1
Authority
AT
Austria
Prior art keywords
compounds
amino acid
fgfr
acid sequences
lpa
Prior art date
Application number
AT04739024T
Other languages
English (en)
Inventor
Morten Albrechtsen
Elisabeth Bock
Vladimir Berezin
Arne Holm
Original Assignee
Enkam Pharmaceuticals As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enkam Pharmaceuticals As filed Critical Enkam Pharmaceuticals As
Application granted granted Critical
Publication of ATE469921T1 publication Critical patent/ATE469921T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
AT04739024T 2003-08-07 2004-08-06 Lpa-haltige verbindungen ATE469921T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301141 2003-08-07
DKPA200400814 2004-05-25
PCT/DK2004/000527 WO2005014623A2 (en) 2003-08-07 2004-08-06 Compounds comprising lpa

Publications (1)

Publication Number Publication Date
ATE469921T1 true ATE469921T1 (de) 2010-06-15

Family

ID=34137357

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04739024T ATE469921T1 (de) 2003-08-07 2004-08-06 Lpa-haltige verbindungen

Country Status (11)

Country Link
US (1) US20090105149A1 (de)
EP (1) EP1660539B1 (de)
JP (1) JP2007526898A (de)
AT (1) ATE469921T1 (de)
AU (1) AU2004263203A1 (de)
BR (1) BRPI0413373A (de)
CA (1) CA2534355A1 (de)
DE (1) DE602004027508D1 (de)
IL (1) IL173532A0 (de)
MX (1) MXPA06001501A (de)
WO (1) WO2005014623A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1434798B1 (de) * 2001-08-17 2012-04-04 Enkam Pharmaceuticals A/S Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
US7847058B2 (en) * 2003-09-30 2010-12-07 Elisabeth Bock Method of modulating cell survival, differentiation and/or synaptic plasticity
US8415298B2 (en) 2004-06-21 2013-04-09 The Board Of Trustees Of The Leland Stanford Junior University Of Stanford Administration of FGF2 for treamtent of anxiety
DK2564864T3 (en) * 2005-11-12 2015-04-07 Trustees Of The Leland Board Of FGF-2 related methods for the diagnosis and treatment of depression
JP5124486B2 (ja) 2006-02-14 2013-01-23 ビーエーエスエフ ソシエタス・ヨーロピア 触媒の存在でモノエチレングリコール及びアンモニアの水素化アミノ化によるエチレンアミン及びエタノールアミンの製造方法
JP4938802B2 (ja) 2006-02-14 2012-05-23 ビーエーエスエフ ソシエタス・ヨーロピア モノエチレングリコール（ｍｅｇ）からのエチレンアミン及びエタノールアミンの製造方法
EP2412726B1 (de) 2006-02-14 2016-06-15 University Of Tasmania Through The Menzies Research Institute Von Metallothionein abgeleitete Peptidfragmente
EP2120967B1 (de) * 2006-11-28 2015-10-21 University Of Southern California Verfahren zur förderung der wundheilung
EP2225272B1 (de) * 2007-11-28 2015-10-21 Enkam Pharmaceuticals A/S Aus ncam (fgls) gewonnene peptide
WO2009100724A1 (en) * 2008-02-11 2009-08-20 Kobenhavns Universitet Novel peptide derived from ncam (bcl)
CN102869775A (zh) 2009-09-30 2013-01-09 哈佛大学校长及研究员协会 通过调节自噬抑制基因产物调节自噬的方法
EP2854836B1 (de) 2012-06-05 2018-04-04 The Board of Trustees of The Leland Stanford Junior University Ncam-peptidmimetika zur behandlung von depression
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
JP2016523125A (ja) 2013-05-30 2016-08-08 グラハム エイチ． クリーシー 局所神経性刺激
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
LT3464336T (lt) 2016-06-01 2022-05-10 Athira Pharma, Inc. Junginiai
KR102562469B1 (ko) 2017-11-07 2023-08-01 뉴로스팀 오에이비, 인크. 적응형 회로를 구비한 비침습성 신경 활성화기
CN114126704B (zh) 2019-06-26 2026-02-03 神经科学技术有限责任公司 具有自适应电路的非侵入性神经激活器
EP4017580A4 (de) 2019-12-16 2023-09-06 Neurostim Technologies LLC Nicht-invasiver nervenaktivator mit verstärkter ladungsabgabe

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629291A (en) * 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US5840689A (en) * 1993-10-29 1998-11-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for stimulating the regrowth of neurons
US5693488A (en) * 1994-05-12 1997-12-02 The Rockefeller University Transmembrane tyrosine phosphatase, nucleic acids encoding the same, and methods of use thereof
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US6313265B1 (en) * 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
ATE254137T1 (de) * 1998-09-29 2003-11-15 Statens Seruminstitut ßLIGAND PRESENTING ASSEMBLYß (LPA), VERFAHREN ZU DESSEN HERSTELLUNG UND VERWENDUNGEN
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US7167819B1 (en) * 1999-05-26 2007-01-23 Chiron Corporation Method of determining the three-dimensional shape of a macromolecule
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
AU7078200A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
WO2002047719A2 (en) * 2000-12-12 2002-06-20 Enkam Pharmaceuticals A/S Survical promoting ncam binding and ncam ligand biding compounds
EP1434798B1 (de) * 2001-08-17 2012-04-04 Enkam Pharmaceuticals A/S Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
US20050222041A1 (en) * 2001-09-05 2005-10-06 Enkam Pharmaceuticals A/S Ncam binding compounds
EP1579218A2 (de) * 2002-12-20 2005-09-28 Enkam Pharmaceuticals A/S Verfahren zur modulation der wechselwerkung von rezeptor und ligand

Also Published As

Publication number Publication date
DE602004027508D1 (de) 2010-07-15
WO2005014623A3 (en) 2005-09-09
BRPI0413373A (pt) 2006-10-17
CA2534355A1 (en) 2005-02-17
EP1660539B1 (de) 2010-06-02
JP2007526898A (ja) 2007-09-20
WO2005014623A2 (en) 2005-02-17
AU2004263203A1 (en) 2005-02-17
EP1660539A2 (de) 2006-05-31
MXPA06001501A (es) 2006-09-04
US20090105149A1 (en) 2009-04-23
IL173532A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
ATE469921T1 (de) Lpa-haltige verbindungen
ATE384526T1 (de) N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes
CL2003001743A1 (es) Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida
BRPI0415288B8 (pt) composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino
DE60311820D1 (de) Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate
ATE386030T1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
MY140710A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2008081701A1 (ja) Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
ATE254630T1 (de) Cyclosporine
WO2005023866A3 (en) Peptides that inhibit complement activation
DE69733272D1 (de) N-(aryl/heteroarylacetyl)aminosäureester, diese enthaltende pharmazeutische zusammensetzungen und methoden zur inhibierung der beta-amyloidfreisetzung und/oder deren synthese unter verwendung dieser verbindungen
WO2007125210A3 (fr) Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer ou de l'inflammation
ATE491463T1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
NO20075227L (no) Treatment of eczemas
DK1561754T3 (da) Fremgangsmåde til fremstilling af 1,2-diaminocyclohexanplatin(II)-komplekser
ATE545655T1 (de) Fgfr-bindende peptide
ATE410437T1 (de) Verfahren und systeme zur rückgewinnung von peptiden
ATE301127T1 (de) Ferrocenylliganden und ein verfahren zur herstellung solcher liganden
ATE533776T1 (de) Analoge verbindungen analgetischer peptide, abgeleitet vom crotalus durissus terrificus schlangengift, ihre verwendungen, zusammensetzungen und verfahren ihrer herstellung und reinigung
DE60235505D1 (de) Neues verfahren und neue zusammensetzung zur hemmurwendung von verbindungen auf basis einer sequenz in mmp-2
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
WO2007045243A3 (en) Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1
ATE505193T1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE60331166D1 (de) Splice variante des menschlichen hypophysären wachstumshormons

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties